Please try another search
Kinnate Biopharma Inc., a precision oncology company, focuses on the discovery, designing, and development of small molecule kinase inhibitors for treating genomically defined cancers in the United States. It develops KIN-3248, a fibroblast growth factor receptors (FGFR) inhibitor, for the treatment of patients with intrahepatic cholangiocarcinoma and urothelial carcinoma, and other solid tumors; and small molecule programs, including KIN-7136, a MEK inhibitor, as well as KIN-8741, an c-MET inhibitor with broad mutational coverage across a variety of solid tumors; and KIN-7324, a cyclin-dependent kinase 4 inhibitor. The company was incorporated in 2018 and is based in San Diego, California. Kinnate Biopharma Inc. operates as a subsidiary of XOMA Corporation.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review